(Shared Conference with Biomarker World Congress and IO Pharma Congress)

Cambridge Healthtech Institute’s 4th Annual

Immuno-Oncology Biomarkers

Predictive Biomarkers and Companion Diagnostics for Cancer Immunotherapy

June 18-19, 2019


As pharmaceutical and biotechnology companies increase their investment in immuno-oncology programs to facilitate rapid development of novel immunotherapies, there is increasing pressure to discover and validate relevant biomarkers. Cambridge Healthtech Institute’s 4th Annual Immuno-Oncology Biomarkers meeting will bring together biomarkers experts from industry and academia to address rapid development of predictive and prognostic IO biomarkers, utility of these biomarkers in clinical trials, and their potential as companion diagnostics.

PATIENT SELECTION BIOMARKERS AND COMPANION DIAGNOSTICS IN IMMUNO-ONCOLOGY

The Role of Pharmacodiagnostics in the Evolving Field of IO Translational Medicine

George A. Green IV, PhD, Executive Director, Precision Medicine, Head, Pharmacodiagnostics, Translational Medicine, Bristol-Myers Squibb

Turning Low Frequency Immuno-Oncology Responses into FDA Approved Therapies: Case Study in Colorectal Cancer

Robert Anders, MD, PhD, Associate Professor, Pathology, Johns Hopkins University

Biomarkers to Stratify Patients Effectively for Personalized Cancer Immunotherapy

Jianda Yuan, MD, PhD, Senior Director, Translational Oncology, Merck

Streamlined CDx– A Proven Strategy to Accelerate Drug Approvals

Jeffery Miller, Founder, CSO & CEO, Invivoscribe     Sponsored by < Invivoscribe >

GENOMIC IO BIOMARKERS AND INTEGRATED BIOMARKER ANALYSIS

Development of a Panel of NGS-Based Immuno-Oncology Biomarkers in Support of Translational Research

Brian Dougherty, PhD, Executive Director, Translational Science, Oncology IMED, AstraZeneca

Emerging IO Biomarkers

Jennifer J.D. Morrissette, PhD, Scientific Director, Clinical Cancer Cytogenetics, Clinical Director, Center for Personalized Diagnostics, University of Pennsylvania

BIOMARKERS TO PREDICT RESPONSE TO IMMUNOTHERAPY

Predictive Markers for Immunotherapy

David L. Rimm, MD, PhD, Professor, Pathology, Yale University

Theranostic Biomarkers for Cancer Immunotherapy

Glen J. Weiss, MD, MBA, Director, Phase I Clinical Research, Beth Israel Deaconess Medical Center, Harvard Medical School

Metabolic Signatures Predictive of Tumor Immune Phenotypes

Samir Hanash, MD, PhD, Director, McCombs Institute for Cancer Early Detection and Treatment, MD Anderson Cancer Center


For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
Email: juliab@healthtech.com

For partnering and sponsorship information, please contact:

Companies A-K
Rod Eymael
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-247-6286
Email: reymael@healthtech.com

Companies L-Z
Joseph Vacca, M.S.
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5431
Email: jvacca@healthtech.com